NaturalVue:

PROTECT RCT Offers New Data in Myopia Correction and Protection

PROTECT stands for PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial

The study is designed to investigate and quantify the safety and effectiveness of NaturalVue® Multifocal Contact Lenses for myopia progression control in children. PROTECT is a 145-subject, multi-center, double-masked, randomized controlled trial with participating investigators in centers in Canada, the United States, Hong Kong, and Singapore.

PROTECT RCT

The Results

Refractive Error

69%
0.41 D

Average reduction in refractive error progression

- The average refractive error reduction was 69%, or 0.41 D vs. control group for year one.

0.18 D

Average refractive error change

- Children wearing NaturalVue Multifocal Contact lenses showed an average refractive error change of 0.18 D.

Axial Length

0.17 MM
59%

Average reduction in axial elongation

- The average axial length reduction was 0.17 mm (59%) vs. control group for year one.

0.12MM

Average axial length change

- The average axial length change in children wearing NaturalVue Multifocal Contact lenses was 0.12 mm.

Note: This is preliminary data, and the 1-year data set will continue to be reviewed and analyzed with additional details to be shared as available. The refractive error change and axial length change standard deviation were ±0.39 and ±0.12 respectively.

Published real-world data indicates Year 2 myopia progression data likely to trend closely with Year 1 values.
Combined with the 6-year data previously published in Clinical Ophthalmology in 2022, and the analysis from 3 independent studies release in September, the one-year data suggests NaturalVue Multifocal may effectively manage eye growth and refractive error change among children.

This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States and is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing clinical trial (RCT) that is studying its effectiveness for myopia progression control.

VTI-RCT-FS1 r2

PROTECT RCT